JP2023548657A5 - - Google Patents
Info
- Publication number
- JP2023548657A5 JP2023548657A5 JP2023521702A JP2023521702A JP2023548657A5 JP 2023548657 A5 JP2023548657 A5 JP 2023548657A5 JP 2023521702 A JP2023521702 A JP 2023521702A JP 2023521702 A JP2023521702 A JP 2023521702A JP 2023548657 A5 JP2023548657 A5 JP 2023548657A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ring
- substituted
- independently selected
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089965P | 2020-10-09 | 2020-10-09 | |
| US63/089,965 | 2020-10-09 | ||
| US202163151468P | 2021-02-19 | 2021-02-19 | |
| US63/151,468 | 2021-02-19 | ||
| PCT/US2021/054191 WO2022076831A2 (en) | 2020-10-09 | 2021-10-08 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548657A JP2023548657A (ja) | 2023-11-20 |
| JP2023548657A5 true JP2023548657A5 (enExample) | 2024-10-15 |
Family
ID=78516928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521702A Pending JP2023548657A (ja) | 2020-10-09 | 2021-10-08 | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240101576A1 (enExample) |
| EP (1) | EP4225445A2 (enExample) |
| JP (1) | JP2023548657A (enExample) |
| KR (1) | KR20230107419A (enExample) |
| AU (1) | AU2021358596A1 (enExample) |
| BR (1) | BR112023006531A2 (enExample) |
| CA (1) | CA3198202A1 (enExample) |
| CL (2) | CL2023001012A1 (enExample) |
| IL (1) | IL301929A (enExample) |
| MX (1) | MX2023004085A (enExample) |
| PH (1) | PH12023500010A1 (enExample) |
| TW (1) | TW202227063A (enExample) |
| WO (1) | WO2022076831A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2023205595A2 (en) * | 2022-04-20 | 2023-10-26 | Celyn Therapeutics, Inc | Egfr inhibitors in cancer treatment |
| CN117946098A (zh) * | 2022-10-28 | 2024-04-30 | 上海深势唯思科技有限责任公司 | 一种嘧啶类plk1抑制剂及其制备方法和用途 |
| US20260217701A1 (en) * | 2022-12-23 | 2026-07-30 | Tay Therapeutics Limited | Selective bet inhibitors and uses thereof |
| CN115819418B (zh) * | 2023-02-14 | 2023-04-28 | 山东绿叶制药有限公司 | Plk1激酶抑制剂及其制备方法和应用 |
| EP4724150A1 (en) | 2023-06-08 | 2026-04-15 | Antares Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| WO2024254298A1 (en) * | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| CN119528906B (zh) * | 2023-08-30 | 2026-06-12 | 中国科学院上海药物研究所 | 氮杂螺环类化合物及其制备方法、药物组合物和应用 |
| EP4534085A1 (en) * | 2023-10-03 | 2025-04-09 | Scorpion Therapeutics, Inc. | Compounds for use in methods of treating cancer |
| WO2025251058A1 (en) * | 2024-05-31 | 2025-12-04 | Celyn Therapeutics, Inc. | Egfr inhibitors in cancer treatment |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906194B2 (en) | 2003-10-08 | 2005-06-14 | Massachusetts Instititue Of Technology | Fluorescence assay for kinase activity |
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| EP3045457B1 (en) * | 2009-06-15 | 2018-05-09 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| JP5825932B2 (ja) | 2011-08-26 | 2015-12-02 | キヤノン株式会社 | 撮像装置及びその制御方法、プログラム、及び記録媒体 |
| CN104125957B (zh) | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| EP2847180B1 (en) | 2012-05-11 | 2017-01-04 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| US20160046604A1 (en) | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP2976336A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| WO2014202590A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| WO2014202583A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| US9745285B2 (en) | 2013-06-21 | 2017-08-29 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| EP3010911A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| CN105764893A (zh) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| TW201613886A (en) | 2014-06-17 | 2016-04-16 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| CN107406417B (zh) * | 2015-01-28 | 2020-06-09 | 拜耳制药股份公司 | 4H-吡咯并[3,2-c]吡啶-4-酮衍生物 |
| CN107922389A (zh) | 2015-06-17 | 2018-04-17 | 拜耳制药股份公司 | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| KR102075886B1 (ko) | 2015-09-01 | 2020-02-11 | 다이호야쿠힌고교 가부시키가이샤 | 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염 |
| WO2019081486A1 (en) * | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| AU2019223168B2 (en) | 2018-02-23 | 2024-09-12 | The Regents Of The University Of Michigan | EGFR dimer disruptors and use of the same |
| JP2021527088A (ja) | 2018-06-14 | 2021-10-11 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｈｅｒ２阻害剤としてのシアノキノリンアミド化合物及び使用方法 |
| US12161649B2 (en) | 2018-06-21 | 2024-12-10 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and methods of use thereof |
| EP3921317B1 (en) * | 2019-02-07 | 2023-08-02 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
-
2021
- 2021-10-08 BR BR112023006531A patent/BR112023006531A2/pt unknown
- 2021-10-08 TW TW110137651A patent/TW202227063A/zh unknown
- 2021-10-08 CA CA3198202A patent/CA3198202A1/en active Pending
- 2021-10-08 EP EP21802493.3A patent/EP4225445A2/en active Pending
- 2021-10-08 IL IL301929A patent/IL301929A/en unknown
- 2021-10-08 AU AU2021358596A patent/AU2021358596A1/en active Pending
- 2021-10-08 MX MX2023004085A patent/MX2023004085A/es unknown
- 2021-10-08 US US18/030,211 patent/US20240101576A1/en active Pending
- 2021-10-08 JP JP2023521702A patent/JP2023548657A/ja active Pending
- 2021-10-08 WO PCT/US2021/054191 patent/WO2022076831A2/en not_active Ceased
- 2021-10-08 KR KR1020237015734A patent/KR20230107419A/ko active Pending
- 2021-10-08 PH PH1/2023/500010A patent/PH12023500010A1/en unknown
-
2023
- 2023-04-06 CL CL2023001012A patent/CL2023001012A1/es unknown
-
2025
- 2025-12-22 CL CL2025004052A patent/CL2025004052A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250059218A1 (en) | ENPP1 Inhibitors and Methods of Modulating Immune Response | |
| TWI825637B (zh) | 啶－１，６（２ｈ，７ｈ）－二酮 | |
| CN118647620A (zh) | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 | |
| KR102793183B1 (ko) | 헤테로시클릭 rip1 키나제 억제제 | |
| CN119841847A (zh) | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 | |
| JP2023543528A5 (enExample) | ||
| JP7491996B2 (ja) | α４β７インテグリンの阻害のための化合物 | |
| AU2016341445B2 (en) | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | |
| JP6530857B2 (ja) | 化合物またはその薬学的に許容される塩もしくは立体異性体、並びにその医薬組成物及び医薬物 | |
| AU2015257456B2 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| EP4720072A2 (en) | Ras inhibitors | |
| AU2022221145A1 (en) | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | |
| JP2021523159A (ja) | Ｅｒｂｂ受容体阻害剤 | |
| CA3147266C (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits | |
| KR20170049604A (ko) | Bub1 억제제로서의 벤질 치환된 인다졸 | |
| PT2791136E (pt) | Triazolpiridinas substituídas e respectiva utilização como inibidores de ttk | |
| JP7706585B2 (ja) | 毛細血管拡張性運動失調症変異（ＡＴＭ）キナーゼの選択的調節物質としての１－イソプロピル－３－メチル－８－（ピリジン－３－イル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］シンノリン－２－オンおよびその使用 | |
| JP2015180675A (ja) | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 | |
| BR112019016373A2 (pt) | conjugados pirrolobenzodiazepina-anticorpo | |
| CN107849036A (zh) | 二环化合物 | |
| JP2024517473A (ja) | Ｙａｐ／ｔｅａｄの調節のための化合物及び方法ならびにそれらの適用 | |
| WO2023036156A1 (zh) | Dna-pk选择性抑制剂及其制备方法和用途 | |
| TW201843151A (zh) | 氘化咪唑并[4,5-c]喹啉-2-酮化合物及其於治療癌症之用途 | |
| JP2025503945A (ja) | Ｙａｐ／ｔｅａｄ調節およびそれらの適応症のための化合物および方法 | |
| US20250376445A1 (en) | Compounds and methods for yap/tead modulation and indications therefor |